ADAP Advocacy has released a new digital commercial highlighting the promise and shortcomings of the 340B Drug Pricing Program, as Congress continues to debate legislation to reform the program. The commercial, part of the organization’s 340B Project, reinforces the central message of a policy paper published earlier this year under the same name, “340B PROGRAM: The Glue That Should Hold Our Healthcare System Together.”
The 340B Program touches nearly every corner of the healthcare ecosystem, serving as a backbone for certain services and providers nationwide, including HIV care. Because the program is so large and consequential, ADAP Advocacy argues that it cannot be left to good faith alone. Instead, the organization calls for improved accountability and transparency guardrails to ensure the program succeeds for its intended beneficiaries: patients.
Brandon M. Macsata, CEO of ADAP Advocacy, said the debate over whether to reform 340B has largely been settled. “The debate surrounding whether to reform the 340B Program has largely been settled, thanks to the growing chorus recognizing the program isn’t living up to the legislative intent,” Macsata stated. “For patients, it is failing to deliver on its promise of expanding affordable healthcare, as shown by the growing medical debt crisis in this country, much of it owed to hospitals. Our new digital commercial moves the debate forward as Congress debates 340B legislation.”
The commercial will air across numerous digital and social platforms. It continues ADAP Advocacy’s 340B Too Big To Fail national advocacy campaign, which highlights hospitals’ declining charity care, rising healthcare executive compensation, and exploding patient medical debt, among other issues. The commercial is available online at https://tinyurl.com/bdea39d2.
ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community members, health care providers, government officials, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient education programs, and foster greater community collaboration.
The new commercial arrives at a critical moment as lawmakers weigh changes to a program that affects drug pricing, hospital revenue, and patient access to care. By taking its message directly to digital and social platforms, ADAP Advocacy aims to shape the public conversation and pressure Congress to adopt reforms that prioritize patients over institutional interests. The outcome of the 340B debate could determine whether the program fulfills its original promise of expanding affordable healthcare or continues to contribute to the nation’s growing medical debt crisis.
